Advertisement

Volume 131, Issue 24

 

 

June 14, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review series: emerging immunotherapies for hematologic diseases.
See the introduction by Sophie Paczesny, Steven Z. Pavletic, and Catherine M. Bollard.

Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque–triggered thrombus formation in humans
In this week’s plenary paper, Busygina et al demonstrate that ibrutinib selectively and irreversibly inhibits platelet aggregation on atherosclerotic plaques, suggesting a novel use of low-dose Bruton tyrosine kinase inhibitors in the prevention of progression of atherosclerosis.


Can thrombophilia predict recurrent catheter-related deep vein thrombosis in children?
Avila and colleagues report that the presence of inherited thrombophilia does not predict for recurrent catheter-related thrombosis in children. Therefore, thrombophilia testing is probably not indicated.


Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
Patients with chronic active hepatitis B (HBV) have an increased risk of diffuse large B-cell lymphoma (DLBCL). Ren and colleagues perform genomic sequencing of hepatitis B surface antigen positive DLBCL patients from China and demonstrate the mutational impact of HBV infection on HBV-related lymphoma.


Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report
Holmqvist et al report on the long-term survival of children undergoing autologous transplantation, demonstrating a 23-fold increase in long-term mortality risk, only half of which was related to disease relapse.


Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS
CUX1 is a critical 7q tumor suppressor gene in human disease. Using an elegant inducible CUX1 knockdown model and shRNA transgenic technology, An et al demonstrate a critical role for CUX1 in hematopoiesis and elucidate the potential role of CUX1 loss in myeloid malignancies.


Introduction to a review series on emerging immunotherapies for hematologic diseases
We present a review series on emerging immunotherapies for hematologic disease, discussing chimeric antigen receptor T cells and their toxicities, vaccine therapies, and cellular therapies for graft-versus-host disease.


The articles in this review series, "Emerging Immunotherapies for Hematologic Diseases":

 

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.